Author Correction: An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients

被引：0
|
作者：
Rajan Ravichandran
Surapaneni Krishna Mohan
Suresh Kumar Sukumaran
Devakumar Kamaraj
Sumetha Suga Daivasuga
Samson Oliver Abraham Samuel Ravi
Sivakumar Vijayaraghavalu
Ramarathnam Krishna Kumar
机构：
[1] MIOT International,Department of Nephrology
[2] Indian Institute of Technology Madras (IITM),Adjunct Faculty
[3] Panimalar Medical College Hospital and Research Institute,Departments of Biochemistry, Molecular Virology and Research
[4] Panimalar Medical College Hospital and Research Institute,Department of General Medicine
[5] Panimalar Medical College Hospital and Research Institute,Departments of Pharmacology and Research
[6] Panimalar Medical College Hospital and Research Institute,Departments of Microbiology and Molecular Virology
[7] Molbio Diagnostics Private Limited,School of Life Sciences
[8] Manipur University,Department of Engineering Design
[9] IITM,undefined
来源：
Scientific Reports | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
    Koshak, Abdulrahman E.
    Koshak, Emad A.
    Mobeireek, Abdullah F.
    Badawi, Mazen A.
    Wali, Siraj O.
    Malibary, Husam M.
    Atwah, Ali F.
    Alhamdan, Meshari M.
    Almalki, Reem A.
    Madani, Tariq A.
    COMPLEMENTARY THERAPIES IN MEDICINE, 2021, 61
  • [32] Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
    Rodriguez-Garcia, Sebastian C.
    Gonzalez-Alvaro, Isidoro
    Abad-Santos, Francisco
    Bautista-Hernandez, Azucena
    Garcia-Fraile, Lucio
    Pablo Baldivieso-Acha, Juan
    Sanz-Sanz, Jesus
    Garcia de Vicuna, Rosario
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 167 - 170
  • [33] Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
    Duarte, Mariano
    Pelorosso, Facundo
    Nicolosi, Liliana N.
    Salgado, M. Victoria
    Vetulli, Hector
    Aquieri, Analia
    Azzato, Francisco
    Castro, Marcela
    Coyle, Javier
    Davolos, Ignacio
    Criado, Ignacio Fernandez
    Gregori, Rosana
    Mastrodonato, Pedro
    Rubio, Maria C.
    Sarquis, Sergio
    Wahlmann, Fernando
    Rothlin, Rodolfo P.
    ECLINICALMEDICINE, 2021, 37
  • [34] Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
    Mohammad Bosaeed
    Ebrahim Mahmoud
    Ahmad Alharbi
    Hadeel Altayib
    Hawra Albayat
    Faisal Alharbi
    Khalid Ghalilah
    Abdulmajid Al Arfaj
    Jumana AlJishi
    Abdullatif Alarfaj
    Hajar Alqahtani
    Badriah M. Almutairi
    Manar Almaghaslah
    Nawaf M. Alyahya
    Abdullah Bawazir
    Saud AlEisa
    Abdulrahman Alsaedy
    Abderrezak Bouchama
    Malak Alharbi
    Majid AlShamrani
    Sameera Al Johani
    Majed Aljeraisy
    Mohammed Alzahrani
    Abdulhakeem O. Althaqafi
    Hassan Almarhabi
    Athari Alotaibi
    Nasser Alqahtani
    Yaseen M. Arabi
    Omar S. Aldibasi
    Ahmad Alaskar
    Infectious Diseases and Therapy, 2021, 10 : 2291 - 2307
  • [35] Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
    Bosaeed, Mohammad
    Mahmoud, Ebrahim
    Alharbi, Ahmad
    Altayib, Hadeel
    Albayat, Hawra
    Alharbi, Faisal
    Ghalilah, Khalid
    Al Arfaj, Abdulmajid
    AlJishi, Jumana
    Alarfaj, Abdullatif
    Alqahtani, Hajar
    Almutairi, Badriah M.
    Almaghaslah, Manar
    Alyahya, Nawaf M.
    Bawazir, Abdullah
    AlEisa, Saud
    Alsaedy, Abdulrahman
    Bouchama, Abderrezak
    Alharbi, Malak
    AlShamrani, Majid
    Al Johani, Sameera
    Aljeraisy, Majed
    Alzahrani, Mohammed
    Althaqafi, Abdulhakeem O.
    Almarhabi, Hassan
    Alotaibi, Athari
    Alqahtani, Nasser
    Arabi, Yaseen M.
    Aldibasi, Omar S.
    Alaskar, Ahmad
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2291 - 2307
  • [36] Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
    Chen, Chang
    Zhang, Yi
    Huang, Jianying
    Yin, Ping
    Cheng, Zhenshun
    Wu, Jianyuan
    Chen, Song
    Zhang, Yongxi
    Chen, Bo
    Lu, Mengxin
    Luo, Yongwen
    Ju, Lingao
    Zhang, Jingyi
    Wang, Xinghuan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
    Siripongboonsitti, Taweegrit
    Ungtrakul, Teerapat
    Tawinprai, Kriangkrai
    Nimmol, Tararin
    Buttakosa, Mullika
    Sornsamdang, Gaidganok
    Jarrusrojwuttikul, Tanadul
    Silapant, Phumin
    Mahanonda, Nithi
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 134 : 211 - 219
  • [38] Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial
    Kumar, G. Sunil
    Vadgaonkar, Atul
    Purunaik, Srilata
    Shelatkar, Rohit
    Vaidya, Vidyadhar G., Sr.
    Ganu, Gayatri
    Vadgaonkar, Aditya
    Joshi, Shashank
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [39] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
    Philippe Bégin
    Jeannie Callum
    Erin Jamula
    Richard Cook
    Nancy M. Heddle
    Alan Tinmouth
    Michelle P. Zeller
    Guillaume Beaudoin-Bussières
    Luiz Amorim
    Renée Bazin
    Kent Cadogan Loftsgard
    Richard Carl
    Michaël Chassé
    Melissa M. Cushing
    Nick Daneman
    Dana V. Devine
    Jeannot Dumaresq
    Dean A. Fergusson
    Caroline Gabe
    Marshall J. Glesby
    Na Li
    Yang Liu
    Allison McGeer
    Nancy Robitaille
    Bruce S. Sachais
    Damon C. Scales
    Lisa Schwartz
    Nadine Shehata
    Alexis F. Turgeon
    Heidi Wood
    Ryan Zarychanski
    Andrés Finzi
    Donald M. Arnold
    Nature Medicine, 2021, 27 : 2012 - 2024
  • [40] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
    Begin, Philippe
    Callum, Jeannie
    Jamula, Erin
    Cook, Richard
    Heddle, Nancy M.
    Tinmouth, Alan
    Zeller, Michelle P.
    Beaudoin-Bussieres, Guillaume
    Amorim, Luiz
    Bazin, Renee
    Loftsgard, Kent Cadogan
    Carl, Richard
    Chasse, Michael
    Cushing, Melissa M.
    Daneman, Nick
    Devine, Dana, V
    Dumaresq, Jeannot
    Fergusson, Dean A.
    Gabe, Caroline
    Glesby, Marshall J.
    Li, Na
    Liu, Yang
    McGeer, Allison
    Robitaille, Nancy
    Sachais, Bruce S.
    Scales, Damon C.
    Schwartz, Lisa
    Shehata, Nadine
    Turgeon, Alexis F.
    Wood, Heidi
    Zarychanski, Ryan
    Finzi, Andres
    Arnold, Donald M.
    NATURE MEDICINE, 2021, 27 (11) : 2012 - +
12345